Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions,
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink Partners Global Healthcare Conference in Miami, Florida on Monday, March 10, 2025 at 3:00 p.m. Eastern Time.
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need.
Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...
Hosted on MSN13d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners ...
Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for argenx in a research report issued to clients ...
Hosted on MSN1mon
Leerink keeps Eli Lilly stock outperform on revenue growthOn Friday, Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical ...
Molecular Partners will present at TD Cowen and Leerink healthcare conferences and host a financial results call on March 7. Molecular Partners AG, a clinical-stage biotech company focused on ...
Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...
Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback